Exact Sciences Corp Financials

EXAS

Source SEC Filings (10-K/10-Q) Updated Feb 13, 2026 Currency USD FYE February

This page shows Exact Sciences Corp (EXAS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 50/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Exact Sciences Corp has an operating margin of 6.3%, meaning the company retains $6 of operating profit per $100 of revenue. This results in a moderate score of 32/100, indicating healthy but not exceptional operating efficiency. This is up from -38.0% the prior year.

Growth

Exact Sciences Corp's revenue declined 99.9% year-over-year, from $2.8B to $3.2M. This contraction results in a growth score of 0/100.

Leverage

100

Exact Sciences Corp carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 2.43, Exact Sciences Corp holds $2.43 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 77/100.

Cash Flow

Exact Sciences Corp has a free cash flow margin of 11.0%, earning a moderate score of 55/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Exact Sciences Corp's ROE of 8.7% shows moderate profitability relative to equity, earning a score of 35/100.

Altman Z-Score Safe

3406.41

Exact Sciences Corp scores 3406.41, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($19.6B) relative to total liabilities ($3.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Strong

7/9

Exact Sciences Corp passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.36x

For every $1 of reported earnings, Exact Sciences Corp generates $2.36 in operating cash flow ($491K OCF vs $208K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

6.3x

Exact Sciences Corp earns $6.3 in operating income for every $1 of interest expense ($206K vs $33K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Revenue

$3.2M

YoY-99.9%

5Y CAGR-70.7%

10Y CAGR-22.1%

Exact Sciences Corp generated $3.2M in revenue in fiscal year 2025. This represents a decrease of 99.9% from the prior year.

EBITDA

$434K

YoY+100.1%

Exact Sciences Corp's EBITDA was $434K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.1% from the prior year.

Free Cash Flow

$357K

YoY-99.5%

5Y CAGR-65.3%

Exact Sciences Corp generated $357K in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 99.5% from the prior year.

Net Income

$208K

YoY+100.0%

Exact Sciences Corp reported $208K in net income in fiscal year 2025. This represents an increase of 100.0% from the prior year.

EPS (Diluted)

$1.10

YoY+119.7%

Exact Sciences Corp earned $1.10 per diluted share (EPS) in fiscal year 2025. This represents an increase of 119.7% from the prior year.

Cash & Debt

$956K

YoY-99.8%

5Y CAGR-77.0%

10Y CAGR-31.4%

Exact Sciences Corp held $956K in cash against $50 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

191M

YoY+2.8%

5Y CAGR+3.7%

10Y CAGR+7.0%

Exact Sciences Corp had 191M shares outstanding in fiscal year 2025. This represents an increase of 2.8% from the prior year.

Gross Margin

69.7%

YoY+0.1pp

5Y CAGR-6.6pp

10Y CAGR+31.8pp

Exact Sciences Corp's gross margin was 69.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.1 percentage points from the prior year.

Operating Margin

6.3%

YoY+44.4pp

5Y CAGR+57.8pp

10Y CAGR+409.7pp

Exact Sciences Corp's operating margin was 6.3% in fiscal year 2025, reflecting core business profitability. This is up 44.4 percentage points from the prior year.

Net Margin

6.4%

YoY+43.7pp

5Y CAGR+61.6pp

10Y CAGR+406.5pp

Exact Sciences Corp's net profit margin was 6.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 43.7 percentage points from the prior year.

Return on Equity

8.7%

Exact Sciences Corp's ROE was 8.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

R&D Spending

$523K

YoY-99.9%

5Y CAGR-75.2%

10Y CAGR-34.1%

Exact Sciences Corp invested $523K in research and development in fiscal year 2025. This represents a decrease of 99.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$135K

YoY-99.9%

5Y CAGR-70.9%

10Y CAGR-39.4%

Exact Sciences Corp invested $135K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 99.9% from the prior year.

EXAS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$3.2M-99.9%	$2.8B+10.4%	$2.5B+19.9%	$2.1B+17.9%	$1.8B+18.5%	$1.5B
Cost of Revenue	$984K-99.9%	$840.1M+13.9%	$737.6M+11.5%	$661.4M+44.2%	$458.8M+29.5%	$354.3M
Gross Profit	$2.3M-99.9%	$1.9B+8.9%	$1.8B+23.8%	$1.4B+8.8%	$1.3B+15.1%	$1.1B
R&D Expenses	$523K-99.9%	$431.2M+1.0%	$426.9M+8.3%	$394.2M+2.2%	$385.6M-30.4%	$554.1M
SG&A Expenses	$889K-99.9%	$781.8M-2.3%	$800.3M+20.6%	$663.4M-17.2%	$801.3M+66.4%	$481.4M
Operating Income	$206K+100.0%	-$1.0B-387.7%	-$215.0M+63.8%	-$593.5M+30.6%	-$855.7M-11.5%	-$767.7M
Interest Expense	$33K-99.9%	$22.3M+14.7%	$19.4M-1.0%	$19.6M+5.5%	$18.6M-72.6%	$67.9M
Income Tax	$4K+100.1%	-$7.3M-404.0%	$2.4M+126.5%	-$9.1M+96.3%	-$246.9M-4423.3%	-$5.5M
Net Income	$208K+100.0%	-$1.0B-404.0%	-$204.1M+67.3%	-$623.5M-4.7%	-$595.6M+27.7%	-$823.6M
EPS (Diluted)	$1.10+119.7%	$-5.59-394.7%	$-1.13+68.1%	$-3.54-1.7%	$-3.48+36.1%	$-5.45

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$878.4M+3.2%	$850.7M+4.9%	$811.1M+14.8%	$706.8M-0.9%	$713.4M+0.7%	$708.7M+1.3%	$699.3M+9.7%	$637.5M
Cost of Revenue	$262.6M-1.6%	$266.8M+7.3%	$248.6M+20.6%	$206.2M-6.6%	$220.8M+1.7%	$217.2M+2.9%	$210.9M+10.3%	$191.2M
Gross Profit	$615.8M+5.5%	$583.9M+3.8%	$562.5M+12.4%	$500.5M+1.6%	$492.6M+0.2%	$491.5M+0.6%	$488.3M+9.4%	$446.3M
R&D Expenses	$191.5M+63.3%	$117.3M+7.7%	$108.9M+3.4%	$105.3M+7.8%	$97.7M-3.7%	$101.5M-16.2%	$121.1M+9.3%	$110.9M
SG&A Expenses	$218.0M-9.7%	$241.4M+15.7%	$208.6M-5.5%	$220.7M+15.5%	$191.1M-1.3%	$193.5M+9.0%	$177.5M-19.2%	$219.7M
Operating Income	-$82.6M-223.3%	-$25.5M-1089.2%	-$2.1M+97.8%	-$96.0M+89.0%	-$876.4M-2124.1%	-$39.4M-50.1%	-$26.3M+75.4%	-$106.7M
Interest Expense	$5.0M-49.3%	$9.8M-0.5%	$9.8M+18.8%	$8.3M+26.0%	$6.6M-31.6%	$9.6M+8755.0%	-$111K-101.8%	$6.2M
Income Tax	$872K-52.5%	$1.8M+62.9%	$1.1M+403.6%	$224K+102.0%	-$11.4M-1508.5%	$808K-44.8%	$1.5M-19.0%	$1.8M
Net Income	-$86.0M-338.7%	-$19.6M-1553.5%	-$1.2M+98.8%	-$101.2M+88.3%	-$864.6M-2161.2%	-$38.2M-141.9%	-$15.8M+85.7%	-$110.2M
EPS (Diluted)	$-0.45-350.0%	$-0.10-900.0%	$-0.01+98.1%	$-0.54+88.4%	$-4.67-2123.8%	$-0.21-133.3%	$-0.09+85.0%	$-0.60

EXAS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$5.9M-99.9%	$5.9B-8.4%	$6.5B+3.9%	$6.2B-6.9%	$6.7B+35.7%	$4.9B
Current Assets	$1.6M-99.9%	$1.6B+31.6%	$1.2B+21.6%	$982.3M-31.1%	$1.4B-35.1%	$2.2B
Cash & Equivalents	$956K-99.8%	$600.9M-0.7%	$605.4M+149.6%	$242.5M-23.1%	$315.5M-78.8%	$1.5B
Inventory	$166K-99.9%	$162.4M+27.4%	$127.5M+7.8%	$118.3M+12.6%	$105.0M+13.8%	$92.3M
Accounts Receivable	$299K-99.9%	$249.0M+22.3%	$203.6M+28.8%	$158.0M-27.0%	$216.6M-7.1%	$233.2M
Goodwill	$2.4M-99.9%	$2.4B0.0%	$2.4B+0.9%	$2.3B+0.5%	$2.3B+88.7%	$1.2B
Total Liabilities	$3.5M-99.9%	$3.5B+6.0%	$3.3B+4.5%	$3.2B-3.4%	$3.3B+22.6%	$2.7B
Current Liabilities	$641K-99.9%	$732.2M+42.3%	$514.7M+24.7%	$412.7M-20.2%	$517.1M-18.3%	$633.1M
Long-Term Debt	$50	N/A	$50.0M	N/A	N/A	$23.8M
Total Equity	$2.4M-99.9%	$2.4B-23.6%	$3.1B+3.4%	$3.0B-10.2%	$3.4B+51.5%	$2.2B
Retained Earnings	$4.7M+100.1%	-$4.5B-29.7%	-$3.5B-6.3%	-$3.3B-23.6%	-$2.6B-29.1%	-$2.0B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$5.9B-0.7%	$5.9B+1.8%	$5.8B+1.5%	$5.7B-3.7%	$5.9B-12.2%	$6.7B+1.1%	$6.7B+4.7%	$6.4B
Current Assets	$1.6B-2.2%	$1.6B+5.5%	$1.5B+10.0%	$1.4B-12.8%	$1.6B+2.5%	$1.5B+5.6%	$1.5B+29.7%	$1.1B
Cash & Equivalents	$956.0M+21.2%	$789.0M+20.1%	$657.1M+89.3%	$347.1M-42.2%	$600.9M+2.0%	$588.8M+11.1%	$530.2M+52.6%	$347.5M
Inventory	$166.2M+0.9%	$164.8M-3.9%	$171.5M-2.9%	$176.6M+8.7%	$162.4M+18.5%	$137.0M+7.5%	$127.4M-0.9%	$128.5M
Accounts Receivable	$298.7M-2.4%	$306.1M-13.4%	$353.3M+26.3%	$279.8M+12.4%	$249.0M-6.0%	$264.8M+0.4%	$263.9M+9.7%	$240.6M
Goodwill	$2.4B0.0%	$2.4B0.0%	$2.4B0.0%	$2.4B0.0%	$2.4B0.0%	$2.4B0.0%	$2.4B0.0%	$2.4B
Total Liabilities	$3.5B+1.8%	$3.4B+2.1%	$3.3B+0.4%	$3.3B-6.0%	$3.5B-0.3%	$3.5B+1.6%	$3.5B+7.3%	$3.2B
Current Liabilities	$641.2M+9.7%	$584.3M+11.9%	$521.9M+3.9%	$502.5M-31.4%	$732.2M+1.2%	$723.7M+8.2%	$668.6M-2.4%	$685.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.4B-4.0%	$2.5B+1.3%	$2.5B+3.0%	$2.4B-0.2%	$2.4B-25.2%	$3.2B+0.6%	$3.2B+1.9%	$3.1B
Retained Earnings	-$4.7B-1.9%	-$4.6B-0.4%	-$4.6B0.0%	-$4.6B-2.3%	-$4.5B-23.8%	-$3.6B-1.1%	-$3.6B-0.4%	-$3.6B

EXAS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$491K-99.8%	$210.5M+34.9%	$156.1M+169.8%	-$223.6M-118.7%	-$102.2M-174.9%	$136.5M
Capital Expenditures	$135K-99.9%	$136.0M+9.5%	$124.2M-42.1%	$214.5M+58.0%	$135.8M+108.6%	$65.1M
Free Cash Flow	$357K-99.5%	$74.5M+133.5%	$31.9M+107.3%	-$438.0M-84.0%	-$238.0M-433.3%	$71.4M
Investing Cash Flow	$195K+100.0%	-$442.2M-990.0%	$49.7M-32.9%	$74.1M+106.8%	-$1.1B-54.1%	-$702.0M
Financing Cash Flow	$338K-99.9%	$231.9M+45.1%	$159.8M+108.9%	$76.5M+802.8%	$8.5M-99.5%	$1.9B
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$151.7M-31.0%	$219.9M+147.1%	$89.0M+188.9%	$30.8M-34.5%	$47.1M-66.1%	$138.7M+29.6%	$107.1M+230.1%	-$82.3M
Capital Expenditures	$31.2M+4.5%	$29.9M-29.4%	$42.3M+35.8%	$31.2M-14.2%	$36.3M+38.8%	$26.2M-27.1%	$35.9M-4.7%	$37.6M
Free Cash Flow	$120.4M-36.6%	$190.0M+307.1%	$46.7M+12887.7%	-$365K-103.4%	$10.7M-90.5%	$112.6M+58.1%	$71.2M+159.4%	-$120.0M
Investing Cash Flow	$91.1M+205.4%	-$86.5M-138.4%	$224.9M+753.1%	-$34.4M+17.8%	-$41.9M+48.8%	-$81.7M+44.5%	-$147.1M+14.2%	-$171.4M
Financing Cash Flow	-$75.9M-4852.5%	-$1.5M+66.1%	-$4.5M+98.2%	-$256.2M-2540.0%	$10.5M+4745.6%	-$226K-100.1%	$224.6M+7581.8%	-$3.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

EXAS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	69.7%+0.1pp	69.5%-0.9pp	70.5%+2.2pp	68.3%-5.8pp	74.0%-2.2pp	76.2%
Operating Margin	6.3%+44.4pp	-38.0%-29.4pp	-8.6%+19.9pp	-28.5%+19.9pp	-48.4%+3.1pp	-51.5%
Net Margin	6.4%+43.7pp	-37.3%-29.1pp	-8.2%+21.7pp	-29.9%+3.8pp	-33.7%+21.5pp	-55.2%
Return on Equity	8.7%	N/A	N/A	N/A	N/A	N/A
Return on Assets	3.5%+20.9pp	-17.4%-14.2pp	-3.1%+6.9pp	-10.0%-1.1pp	-8.9%+7.8pp	-16.7%
Current Ratio	2.43+0.3	2.15-0.2	2.32-0.1	2.38-0.4	2.76-0.7	3.47
Debt-to-Equity	0.00-1.5	1.47+1.5	0.02-1.0	1.05+0.1	0.97+1.0	0.01
FCF Margin	11.0%+8.3pp	2.7%+1.4pp	1.3%+22.3pp	-21.0%-7.6pp	-13.5%-18.3pp	4.8%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	70.1%+1.5pp	68.6%-0.7pp	69.3%-1.5pp	70.8%+1.8pp	69.0%-0.3pp	69.3%-0.5pp	69.8%-0.2pp	70.0%
Operating Margin	-9.4%-6.4pp	-3.0%-2.7pp	-0.3%+13.3pp	-13.6%+109.3pp	-122.8%-117.3pp	-5.6%-1.8pp	-3.8%+13.0pp	-16.7%
Net Margin	-9.8%-7.5pp	-2.3%-2.1pp	-0.1%+14.2pp	-14.3%+106.9pp	-121.2%-115.8pp	-5.4%-3.1pp	-2.3%+15.0pp	-17.3%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-1.5%-1.1pp	-0.3%-0.3pp	-0.0%+1.8pp	-1.8%+12.8pp	-14.6%-14.0pp	-0.6%-0.3pp	-0.2%+1.5pp	-1.7%
Current Ratio	2.43-0.3	2.72-0.2	2.89+0.2	2.73+0.6	2.15+0.0	2.12-0.1	2.17+0.5	1.64
Debt-to-Equity	1.44+0.1	1.36+0.0	1.35-0.0	1.38-0.1	1.47+0.4	1.10+0.0	1.09+0.1	1.04
FCF Margin	13.7%-8.6pp	22.3%+16.6pp	5.8%+5.8pp	-0.1%-1.6pp	1.5%-14.4pp	15.9%+5.7pp	10.2%+29.0pp	-18.8%

Similar Companies

PERKINELMER INC PKI

$14.5B

Illumina Inc ILMN

$17.8B

Medpace Holdings MEDP

$12.2B

ICON PLC ICLR

$6.8B

Waters WAT

$31.5B

Frequently Asked Questions

What is Exact Sciences Corp's annual revenue?

Exact Sciences Corp (EXAS) reported $3.2M in total revenue for fiscal year 2025. This represents a -99.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Exact Sciences Corp's revenue growing?

Exact Sciences Corp (EXAS) revenue declined by 99.9% year-over-year, from $2.8B to $3.2M in fiscal year 2025.

Is Exact Sciences Corp profitable?

Yes, Exact Sciences Corp (EXAS) reported a net income of $208K in fiscal year 2025, with a net profit margin of 6.4%.

What is Exact Sciences Corp's earnings per share (EPS)?

Exact Sciences Corp (EXAS) reported diluted earnings per share of $1.10 for fiscal year 2025. This represents a 119.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Exact Sciences Corp's EBITDA?

Exact Sciences Corp (EXAS) had EBITDA of $434K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Exact Sciences Corp have?

As of fiscal year 2025, Exact Sciences Corp (EXAS) had $956K in cash and equivalents against $50 in long-term debt.

What is Exact Sciences Corp's gross margin?

Exact Sciences Corp (EXAS) had a gross margin of 69.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Exact Sciences Corp's operating margin?

Exact Sciences Corp (EXAS) had an operating margin of 6.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Exact Sciences Corp's net profit margin?

Exact Sciences Corp (EXAS) had a net profit margin of 6.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Exact Sciences Corp's return on equity (ROE)?

Exact Sciences Corp (EXAS) has a return on equity of 8.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Exact Sciences Corp's free cash flow?

Exact Sciences Corp (EXAS) generated $357K in free cash flow during fiscal year 2025. This represents a -99.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Exact Sciences Corp's operating cash flow?

Exact Sciences Corp (EXAS) generated $491K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Exact Sciences Corp's total assets?

Exact Sciences Corp (EXAS) had $5.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Exact Sciences Corp's capital expenditures?

Exact Sciences Corp (EXAS) invested $135K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Exact Sciences Corp spend on research and development?

Exact Sciences Corp (EXAS) invested $523K in research and development during fiscal year 2025.

How many shares does Exact Sciences Corp have outstanding?

Exact Sciences Corp (EXAS) had 191M shares outstanding as of fiscal year 2025.

What is Exact Sciences Corp's current ratio?

Exact Sciences Corp (EXAS) had a current ratio of 2.43 as of fiscal year 2025, which is generally considered healthy.

What is Exact Sciences Corp's debt-to-equity ratio?

Exact Sciences Corp (EXAS) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Exact Sciences Corp's return on assets (ROA)?

Exact Sciences Corp (EXAS) had a return on assets of 3.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Exact Sciences Corp's Altman Z-Score?

Exact Sciences Corp (EXAS) has an Altman Z-Score of 3406.41, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Exact Sciences Corp's Piotroski F-Score?

Exact Sciences Corp (EXAS) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Exact Sciences Corp's earnings high quality?

Exact Sciences Corp (EXAS) has an earnings quality ratio of 2.36x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Exact Sciences Corp cover its interest payments?

Exact Sciences Corp (EXAS) has an interest coverage ratio of 6.3x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Exact Sciences Corp?

Exact Sciences Corp (EXAS) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.